Alarmins in autoimmune diseases.
Alarmins
Idiopathic inflammatory myopathies
Organ-specific autoimmune diseases
Systemic autoimmune diseases
Systemic lupus erythematosus
Vasculitides
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
29
06
2022
accepted:
10
07
2022
pubmed:
20
7
2022
medline:
18
8
2022
entrez:
19
7
2022
Statut:
ppublish
Résumé
Alarmins are endogenous, constitutively expressed, chemotacting and immune activating proteins or peptides released because of non-programmed cell death (i.e. infections, trauma, etc). They are considered endogenous damage-associated molecular patterns (DAMPs), able to induce a sterile inflammation. In the last years, several studies highlighted a possible role of different alarmins in the pathogenesis of various autoimmune and immune-mediated diseases. We reviewed the relevant literature about this topic, for about 160 articles. Particularly, we focused on systemic autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, idiopathic inflammatory myopathies, ANCA-associated vasculitides, Behçet's disease) and cutaneous organ-specific autoimmune diseases (vitiligo, psoriasis, alopecia, pemphigo). Finally, we discussed about future perspectives and potential therapeutic implications of alarmins in autoimmune diseases. In fact, identification of receptors and downstream signal transducers of alarmins may lead to the identification of antagonistic inhibitors and agonists, with the capacity to modulate alarmins-related pathways and potential therapeutic applicability.
Identifiants
pubmed: 35853572
pii: S1568-9972(22)00112-4
doi: 10.1016/j.autrev.2022.103142
pii:
doi:
Substances chimiques
Alarmins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103142Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.